Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease

Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine wou...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2019-08, Vol.74 (2), p.413-420
Main Authors: de Jong, Daan L K, de Heus, Rianne A A, Rijpma, Anne, Donders, Rogier, Olde Rikkert, Marcel G M, Günther, Matthias, Lawlor, Brian A, van Osch, Matthias J P, Claassen, Jurgen A H R
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1632-95212805877ceef5dd12660c17a399e132203ae33fac1abce0e4ac5afb9bff073
cites
container_end_page 420
container_issue 2
container_start_page 413
container_title Hypertension (Dallas, Tex. 1979)
container_volume 74
creator de Jong, Daan L K
de Heus, Rianne A A
Rijpma, Anne
Donders, Rogier
Olde Rikkert, Marcel G M
Günther, Matthias
Lawlor, Brian A
van Osch, Matthias J P
Claassen, Jurgen A H R
description Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P
doi_str_mv 10.1161/HYPERTENSIONAHA.119.12892
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242160555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2242160555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1632-95212805877ceef5dd12660c17a399e132203ae33fac1abce0e4ac5afb9bff073</originalsourceid><addsrcrecordid>eNo1kE1Lw0AYhBdBbK3-BVlvXlL3M2mOsaa2UNqiFfEUNpt36comW7NpRX-9AetpYJgZHgahW0rGlMb0fv6-yZ-3-eplsV5l86w30zFlk5SdoSGVTERCxnyALkP4IIQKIZILNOCUEZ4wOUSb3BjQXcDe4JV1R1XZvW0A-wZPoYWyVQ4_OO8rPHP-C9sGb1Rnoekbb7bb4cz97MDW0OJHG0AFuELnRrkA1ycdoddZvp3Oo-X6aTHNlpGmMWdRKllPSeQkSTSAkVVFWRwTTRPF0xQoZz2hAs6N0lSVGggIpaUyZVoaQxI-Qnd_u_vWfx4gdEVtgwbnVAP-EArGBKMxkVL20ZtT9FDWUBX71taq_S7-X-C_hJFfHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242160555</pqid></control><display><type>article</type><title>Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease</title><source>EZB Electronic Journals Library</source><creator>de Jong, Daan L K ; de Heus, Rianne A A ; Rijpma, Anne ; Donders, Rogier ; Olde Rikkert, Marcel G M ; Günther, Matthias ; Lawlor, Brian A ; van Osch, Matthias J P ; Claassen, Jurgen A H R</creator><creatorcontrib>de Jong, Daan L K ; de Heus, Rianne A A ; Rijpma, Anne ; Donders, Rogier ; Olde Rikkert, Marcel G M ; Günther, Matthias ; Lawlor, Brian A ; van Osch, Matthias J P ; Claassen, Jurgen A H R</creatorcontrib><description>Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P&lt;0.01), while whole-brain gray-matter CBF remained stable (Δ=5.4 [95% CI, -6.4 to 17.2] mL/100 g per minute; P=0.36). CBF in the hippocampus increased (left: Δ=24.4 [95% CI, 4.3-44.5] mL/100 g per minute; P=0.02; right: Δ=20.1 [95% CI, -0.6 to 40.8] mL/100 g per minute; P=0.06). There was no significant change in CBF in the posterior cingulate cortex (Δ=5.2 [95% CI, -16.5 to 27.0] mL/100 g per minute; P=0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02017340.</description><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.119.12892</identifier><identifier>PMID: 31203725</identifier><language>eng</language><publisher>United States</publisher><ispartof>Hypertension (Dallas, Tex. 1979), 2019-08, Vol.74 (2), p.413-420</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1632-95212805877ceef5dd12660c17a399e132203ae33fac1abce0e4ac5afb9bff073</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31203725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Jong, Daan L K</creatorcontrib><creatorcontrib>de Heus, Rianne A A</creatorcontrib><creatorcontrib>Rijpma, Anne</creatorcontrib><creatorcontrib>Donders, Rogier</creatorcontrib><creatorcontrib>Olde Rikkert, Marcel G M</creatorcontrib><creatorcontrib>Günther, Matthias</creatorcontrib><creatorcontrib>Lawlor, Brian A</creatorcontrib><creatorcontrib>van Osch, Matthias J P</creatorcontrib><creatorcontrib>Claassen, Jurgen A H R</creatorcontrib><title>Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P&lt;0.01), while whole-brain gray-matter CBF remained stable (Δ=5.4 [95% CI, -6.4 to 17.2] mL/100 g per minute; P=0.36). CBF in the hippocampus increased (left: Δ=24.4 [95% CI, 4.3-44.5] mL/100 g per minute; P=0.02; right: Δ=20.1 [95% CI, -0.6 to 40.8] mL/100 g per minute; P=0.06). There was no significant change in CBF in the posterior cingulate cortex (Δ=5.2 [95% CI, -16.5 to 27.0] mL/100 g per minute; P=0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02017340.</description><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1kE1Lw0AYhBdBbK3-BVlvXlL3M2mOsaa2UNqiFfEUNpt36comW7NpRX-9AetpYJgZHgahW0rGlMb0fv6-yZ-3-eplsV5l86w30zFlk5SdoSGVTERCxnyALkP4IIQKIZILNOCUEZ4wOUSb3BjQXcDe4JV1R1XZvW0A-wZPoYWyVQ4_OO8rPHP-C9sGb1Rnoekbb7bb4cz97MDW0OJHG0AFuELnRrkA1ycdoddZvp3Oo-X6aTHNlpGmMWdRKllPSeQkSTSAkVVFWRwTTRPF0xQoZz2hAs6N0lSVGggIpaUyZVoaQxI-Qnd_u_vWfx4gdEVtgwbnVAP-EArGBKMxkVL20ZtT9FDWUBX71taq_S7-X-C_hJFfHQ</recordid><startdate>201908</startdate><enddate>201908</enddate><creator>de Jong, Daan L K</creator><creator>de Heus, Rianne A A</creator><creator>Rijpma, Anne</creator><creator>Donders, Rogier</creator><creator>Olde Rikkert, Marcel G M</creator><creator>Günther, Matthias</creator><creator>Lawlor, Brian A</creator><creator>van Osch, Matthias J P</creator><creator>Claassen, Jurgen A H R</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201908</creationdate><title>Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease</title><author>de Jong, Daan L K ; de Heus, Rianne A A ; Rijpma, Anne ; Donders, Rogier ; Olde Rikkert, Marcel G M ; Günther, Matthias ; Lawlor, Brian A ; van Osch, Matthias J P ; Claassen, Jurgen A H R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1632-95212805877ceef5dd12660c17a399e132203ae33fac1abce0e4ac5afb9bff073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Jong, Daan L K</creatorcontrib><creatorcontrib>de Heus, Rianne A A</creatorcontrib><creatorcontrib>Rijpma, Anne</creatorcontrib><creatorcontrib>Donders, Rogier</creatorcontrib><creatorcontrib>Olde Rikkert, Marcel G M</creatorcontrib><creatorcontrib>Günther, Matthias</creatorcontrib><creatorcontrib>Lawlor, Brian A</creatorcontrib><creatorcontrib>van Osch, Matthias J P</creatorcontrib><creatorcontrib>Claassen, Jurgen A H R</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Jong, Daan L K</au><au>de Heus, Rianne A A</au><au>Rijpma, Anne</au><au>Donders, Rogier</au><au>Olde Rikkert, Marcel G M</au><au>Günther, Matthias</au><au>Lawlor, Brian A</au><au>van Osch, Matthias J P</au><au>Claassen, Jurgen A H R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2019-08</date><risdate>2019</risdate><volume>74</volume><issue>2</issue><spage>413</spage><epage>420</epage><pages>413-420</pages><eissn>1524-4563</eissn><abstract>Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P&lt;0.01), while whole-brain gray-matter CBF remained stable (Δ=5.4 [95% CI, -6.4 to 17.2] mL/100 g per minute; P=0.36). CBF in the hippocampus increased (left: Δ=24.4 [95% CI, 4.3-44.5] mL/100 g per minute; P=0.02; right: Δ=20.1 [95% CI, -0.6 to 40.8] mL/100 g per minute; P=0.06). There was no significant change in CBF in the posterior cingulate cortex (Δ=5.2 [95% CI, -16.5 to 27.0] mL/100 g per minute; P=0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02017340.</abstract><cop>United States</cop><pmid>31203725</pmid><doi>10.1161/HYPERTENSIONAHA.119.12892</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1524-4563
ispartof Hypertension (Dallas, Tex. 1979), 2019-08, Vol.74 (2), p.413-420
issn 1524-4563
language eng
recordid cdi_proquest_miscellaneous_2242160555
source EZB Electronic Journals Library
title Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A01%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Nilvadipine%20on%20Cerebral%20Blood%20Flow%20in%20Patients%20With%20Alzheimer%20Disease&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=de%20Jong,%20Daan%20L%20K&rft.date=2019-08&rft.volume=74&rft.issue=2&rft.spage=413&rft.epage=420&rft.pages=413-420&rft.eissn=1524-4563&rft_id=info:doi/10.1161/HYPERTENSIONAHA.119.12892&rft_dat=%3Cproquest_pubme%3E2242160555%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1632-95212805877ceef5dd12660c17a399e132203ae33fac1abce0e4ac5afb9bff073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2242160555&rft_id=info:pmid/31203725&rfr_iscdi=true